Draft Guidance Docs Should Be Transitory, Industry Insists
This article was originally published in The Gray Sheet
Device industry advocates stressed to CDRH during a meeting last week that draft-guidance documents need to more routinely be finalized or withdrawn in an expedited manner, and that agency staffers must resist using the out-for-comment document as if they are settled policy.
You may also be interested in...
Industry Proposes Its FDA Guidance Priorities, Reforms
After FDA published its annual lists of guidance priorities, industry has responded by stating what guidances companies would like to see. Meanwhile, the push for broader reforms to the guidance-development process continues.
CDRH Sets Performance Goals To Reduce Draft Guidance Ambiguity
The device center has committed to metrics for draft guidance documents, trying to address complaints that policies linger too long in the draft stage and create regulatory confusion. CDRH also highlighted recent website upgrades intended to better distinguish between draft and final guidance documents.
Pfizer Says FDA Draft Guidance Is Just Fine; Congress Should Be Patient
In an unusual move, industry rep indicates comfort with draft guidance implementing biosimilar pathway.